In the present study, interplay between (FAT)/CD36 and CPT-1, both higher expressed in treated groups, guarantees the maximum oxidative activity within hepatic mitochondria, enhancing fatty acid metabolization and, thus, reducing hepatic steatosis. Here, CD36 is linked to Hepatic steatosis.